ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Berlin, BE, DEU:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Berlin, Germany and 145 other locations

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Eftozanermin alfa

Phase 1

AbbVie
AbbVie

Berlin, Germany and 18 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Berlin, Germany and 218 other locations

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 140 other locations

The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone (RAD) as comparator arm for Lenalidomide, Bortezomib, Dexameth...

Active, not recruiting
Previously Untreated Symptomatic Multiple Myeloma
Biological: autologous stem cell transplant
Drug: Lenalidomide, Bortezomib

Phase 3

Wuerzburg University Hospital

Berlin, Germany and 31 other locations

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Berlin, Germany and 180 other locations

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

Phase 3

Pfizer
Pfizer

Berlin, Germany and 110 other locations

antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

Phase 3

Pfizer
Pfizer

Berlin, Berlin, Germany and 270 other locations

demonstrate the non-inferiority of subcutaneous to intravenous isatuximab administration in transplant-eligible patients with newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Dexamethasone

Phase 3

University of Heidelberg Medical Center

Berlin, Germany and 80 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Berlin, Germany and 135 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems